GCLCi0
GCLCi0 (ONO-6428513) is a glutamate-cysteine ligase catalytic subunit (GCLC) inhibitor and ferroptosis inducer that blocks the rate-limiting step of glutathione synthesis and exerts anti-tumor activity. GCLCi0 specifically targets SMARCB1-deficient cancer cells, induces reactive oxygen species production and lipid peroxidation. In addition, GCLCi0 shows a significant synergistic effect with SLC7A11 inhibitors and Telaglenastat (HY-12248). GCLCi0 can be used in the research of smarcb1-deficient malignant rhabdoid tumors and smarcb1-deficient epithelioid sarcomas.
For research use only. We do not sell to patients.
- CAS No.: 2926699-71-8
- Formula: C8H15F3N2O3S
- Molecular Weight:276.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
GCLCi0 (72 h) potently and selectively inhibits the viability of SMARCB1-deficient rhabdoid tumor cells (JMU-RTK-2, G401, G402) with significantly lower IC50 values than in SMARCB1-proficient renal cancer cells, displaying a selective index superior to approved EZH2 inhibitors[1].
GCLCi0 (0.1-10 μM; 24-48 h) selectively depletes the GSH/GSSG ratio in SMARCB1-deficient rhabdoid tumor cells (JMU-RTK-2, G401, G402) in a concentration-dependent manner, with minimal effect on SMARCB1-proficient renal cancer cells[1].
GCLCi0 (0.1-4 μM; 72 h) selectively induces concentration-dependent lipid peroxidation in SMARCB1-deficient rhabdoid tumor cells (JMU-RTK-2, G401), an effect that is suppressed by the ferroptosis inhibitor Ferrostatin-1 (HY-100579)[1].
GCLCi0 (72 h) antiproliferative effect on SMARCB1-deficient JMU-RTK-2 rhabdoid tumor cells is rescued by the ferroptosis inhibitor ferrostatin-1 but not by the apoptosis inhibitor Z-VAD-FMK, confirming ferroptosis as the mechanism of cell death[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 2926699-71-8
-
Molecular Weight 276.28
-
Formula C8H15F3N2O3S
-
SMILES
N[C@H](C(O)=O)CCS(=N)(CCCC(F)(F)F)=O
-
Synonyms
ONO-6428513
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- GCLCi0
- 2926699-71-8
- ONO-6428513
- GCLCi 0
- GCLCi-0
- ONO6428513
- ONO 6428513
- Ferroptosis
- ferroptotic cell death
- reactive oxygen species
- epithelioid sarcomas
- JMU-RTK-2
- malignant rhabdoid tumors
- glutathione synthesis
- mouse tumor xenograft models
- glutamate-cysteine ligase catalytic subunit
- lipid peroxidation
- SMARCB1-deficient cancer cells
- Inhibitor
- inhibitor
- inhibit